マルチモーダルイメージング市場 : 2028年までの世界予測

Report Overview

The global multimodal market is projected to reach USD 5.5 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 5.7% from 2023 to 2028. Factors such as the high incidence/prevalence of target diseases, the growing number of diagnostic imaging centers/procedures, increasing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems, features and modalities are responsible for the increasing growth of this market.

“The PET-CT segment of technology segment l held the largest share of the market in 2022”
Based on technology, the multimodal market is segmented into PET-CT, PET/MR, SPECT-CT, OCT/FMT and other multimodal imaging . The PET-CT segment held a major share of the market. Conducting PET and CT scans in a single session reduces radiation exposure and scan time, while its clinical versatility spans oncology, cardiology, neurology, and infectious diseases. Despite initial costs, the cost-effectiveness of PET-CT emerges from improved diagnostics, reduced need for additional tests, and research advancements, making it a valuable tool that significantly benefits patient outcomes and medical research are driving the growth of this product segment.

“The oncology segment is projected to register the highest CAGR during the forecast period”
Based on application, the multimodal market is segmented into brain & neurology, cardiology, oncology, ophthalmology, research and other applications. The oncology segment accounted for the largest market share in 2022. The large share of this segment is attributed to the system’s versatility, image quality, ehanced, easy to use features, and due to the increased usage of it in acute care settings and emergency care in hospitals and healthcare institutions.

“The diagnostic imaging centers segment for end user segment is projected to register a significant CAGR during the forecast period”
On the basis of end user, the multimodal market is segmented into hospitals, diagnostic imaging cneters, academic and research institutes. The diagnostic imaging centers segment accounted for the largest share of the multimodal market in 2022. By integrating multiple imaging modalities, such as PET-CT, MRI-PET, or SPECT-CT, diagnostic imaging centers can provide more accurate and reliable diagnoses, leading to better treatment planning and improved patient outcomes. Moreover, the versatility of multimodal imaging enables these centers to cater to a wide range of medical specialties, effectively serving patients with diverse healthcare needs.

“The market in the North America region is expected to witness the highest growth during the forecast period.”
The multimodal market in the North America region is expected to register a CAGR during the forecast period, primarily due to the high healthcare spending in the region, rising prevalence of target diseases, increasing research activities, growing number of cosmetic surgeries, and technological advancements in imaging systems.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: Director-level–14%, C-level–10%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

The prominent players in the multimodal market are GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Siemens AG (Germany), Neusoft (China), Topcon Corporation (Japan), and Bruker (US) among others.

Research Coverage

This report studies the multimodal market based on technology, display, portability, component, application, enduser, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall multimodal market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:
• Analysis of key drivers (rising target patient population, growing adoption of multimodal imaging devices, technological advancement, and increasing investment, funds, and grants by public-private organizations), restraints (high capital and operational cost, unfavorable regulatory guidelines), opportunities (improving healthcare infrastructure across emerging countries, PET utilization for breast imaging, promising product pipeline), and challenges (availability of alternate imaging technologies) influencing the growth of the multimodal market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the multimodal market
• Market Development: Comprehensive information about lucrative markets–the report analyses the multimodal market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multimodal market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Siemens AG (Germany), Neusoft (China), Topcon Corporation (Japan), and Bruker (US) among others.

Table of Contents

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 GEOGRAPHICAL SEGMENTATION 26
1.4 YEARS CONSIDERED 26
1.5 CURRENCY 27
1.6 RESEARCH LIMITATIONS 27
1.7 STAKEHOLDERS 27
1.8 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 1 MULTIMODAL IMAGING MARKET: RESEARCH DESIGN 29
2.1.1 SECONDARY RESEARCH 30
2.1.2 PRIMARY RESEARCH 31
2.1.2.1 Primary sources 32
2.1.2.2 Key industry insights 33
2.1.2.3 Breakdown of primaries 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION 34
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
2.2.1 BOTTOM-UP APPROACH 36
2.2.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 5 MARKET SIZE ESTIMATION FOR MULTIMODAL IMAGING: APPROACH 1 (COMPANY REVENUE ESTIMATION) 37
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF SIEMENS HEALTHINEERS 38
2.2.1.2 Approach 2: Customer-based market estimation 38
2.2.1.3 Multimodal imaging market: Top-down approach 39
2.2.1.4 Approach 3: CAGR projections 39
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.3 DATA TRIANGULATION 40
FIGURE 8 DATA TRIANGULATION METHODOLOGY 40
2.4 MARKET SHARE ASSESSMENT 41
2.5 STUDY ASSUMPTIONS 41
2.6 GROWTH RATE ASSUMPTIONS 42
2.7 RISK ASSESSMENT 42
2.7.1 MULTIMODAL IMAGING MARKET: RISK ASSESSMENT 42
2.8 RECESSION IMPACT 42
3 EXECUTIVE SUMMARY 44
FIGURE 9 MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2023 VS. 2028  (USD MILLION) 44
FIGURE 10 MULTIMODAL IMAGING MARKET, BY APPLICATION, 2023 VS. 2028  (USD MILLION) 45
FIGURE 11 MULTIMODAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF MULTIMODAL IMAGING MARKET 47
4 PREMIUM INSIGHTS 48
4.1 MULTIMODAL IMAGING MARKET OVERVIEW 48
FIGURE 13 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES  TO DRIVE MARKET 48
4.2 NORTH AMERICA: MULTIMODAL IMAGING MARKET,  BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 49
FIGURE 14 PET/CT MULTIMODAL IMAGING SYSTEMS TO DOMINATE NORTH AMERICAN MARKET IN 2023 49
4.3 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 50
FIGURE 15 HOSPITALS TO DOMINATE ASIA PACIFIC MARKET IN 2023 50
4.4 EUROPE: MULTIMODAL IMAGING MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION) 51
FIGURE 16 ONCOLOGY SEGMENT TO DOMINATE EUROPEAN MARKET DURING FORECAST PERIOD 51
4.5 MULTIMODAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 54
FIGURE 18 MULTIMODAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 54
5.2.1.1 Growing applications of multimodal imaging systems 54
5.2.1.2 Technological advancements in diagnostic imaging modalities 55
TABLE 1 TECHNOLOGICAL ADVANCEMENTS IN MULTIMODAL IMAGING SYSTEMS 55
5.2.1.3 Availability of funding for research 57
5.2.1.4 Increasing establishment of hospitals and diagnostic imaging centers 58
5.2.2 RESTRAINTS 58
5.2.2.1 Unfavorable healthcare reforms 58
5.2.2.2 High capital and operational cost 59
5.2.2.3 Lack of adequate healthcare infrastructure 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Availability of reimbursement and insurance coverage for scans 59
TABLE 2 CODES FOR SPECT/CT FUSION IMAGING (AS OF 2021) 60
TABLE 3 NATIONAL PET, PET/CT COVERAGE FOR ONCOLOGY (AS OF 2021) 60
5.2.3.2 Increasing R&D into radiotracers 61
5.2.4 CHALLENGES 61
5.2.4.1 Growing end-user preference for refurbished equipment 61
5.2.4.2 Dearth of trained professionals 62
5.3 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 4 MULTIMODAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 62
5.3.1 THREAT OF NEW ENTRANTS 62
5.3.2 THREAT OF SUBSTITUTES 63
5.3.3 BARGAINING POWER OF SUPPLIERS 63
5.3.4 BARGAINING POWER OF BUYERS 63
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.4 REGULATORY TRENDS 63
5.4.1 REGULATORY TRENDS FOR MULTIMODAL IMAGING MARKET 63
5.5 REGULATORY ANALYSIS 64
5.5.1 NORTH AMERICA 64
5.5.1.1 US 64
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 64
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.5.1.2 Canada 65
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.5.2 EUROPE 66
5.5.3 ASIA PACIFIC 66
5.5.3.1 Japan 66
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 67
5.5.3.2 China 67
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 67
5.5.3.3 India 68
5.6 REIMBURSEMENT SCENARIO 69
TABLE 10 MEDICAL REIMBURSEMENT CPT CODES FOR MULTIMODAL IMAGING PROCEDURES IN US (AS OF 2021) 69
5.7 ECOSYSTEM MAPPING 70
5.8 VALUE CHAIN ANALYSIS 70
5.8.1 RESEARCH & PRODUCT DEVELOPMENT 70
5.8.2 RAW MATERIAL AND MANUFACTURING 71
5.8.3 MARKETING & SALES, SHIPMENT, AND POST-SALES SERVICES 71
FIGURE 19 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 71
5.9 SUPPLY CHAIN ANALYSIS 72
5.9.1 PROMINENT COMPANIES 72
5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES 72
5.9.3 END USERS 72
TABLE 11 MULTIMODAL IMAGING MARKET: SUPPLY CHAIN ECOSYSTEM 72
FIGURE 20 MULTIMODAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 73
5.10 PATENT ANALYSIS 74
FIGURE 21 PATENTS FOR PET/CT IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 74
FIGURE 22 PATENTS FOR PET/MR IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 75
FIGURE 23 PATENTS FOR SPECT/CT IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 76
FIGURE 24 PATENTS FOR OCT IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 77
5.11 TRADE ANALYSIS 78
5.11.1 MULTIMODAL IMAGING MARKET: TRADE ANALYSIS 78
TABLE 12 IMPORT DATA FOR MULTIMODAL IMAGING (HS CODE 901820), BY COUNTRY,  2018–2022 (USD) 78
TABLE 13 EXPORT DATA FOR MULTIMODAL IMAGING (HS CODE 901820), BY COUNTRY,  2018–2022 (USD) 78
5.12 KEY CONFERENCES AND EVENTS 79
TABLE 14 MULTIMODAL IMAGING MARKET: LIST OF KEY CONFERENCES AND EVENTS (2023–2025) 79
5.13 TECHNOLOGY ANALYSIS 80
5.14 CASE STUDY ANALYSIS 81
TABLE 15 CASE STUDY 1: MAINTAINING STRONG FOCUS ON TECHNOLOGICAL INNOVATION AND ADDRESSING REGULATORY COMPLIANCE 81
TABLE 16 CASE STUDY 2: PROVIDING COMPREHENSIVE TRAINING PROGRAMS FOR EVOLVING MULTIMODAL IMAGING TECHNIQUES 82
5.15 PRICING ANALYSIS 82
TABLE 17 REGION-WISE PRICE RANGE FOR MULTIMODAL IMAGING SYSTEMS 82
6 MULTIMODAL IMAGING MARKET, BY TECHNOLOGY 83
6.1 INTRODUCTION 84
TABLE 18 MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 84
6.2 PET/CT SYSTEMS 84
6.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 84
TABLE 19 PET/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION,  2021–2028 (USD MILLION) 85
TABLE 20 PET/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 86
TABLE 21 PET/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER,  2021–2028 (USD MILLION) 86
6.3 SPECT/CT SYSTEMS 87
6.3.1 INCREASING APPLICATIONS OF SPECT/CT SYSTEMS TO DRIVE MARKET 87
TABLE 22 SPECT/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION,  2021–2028 (USD MILLION) 88
TABLE 23 SPECT/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 88
TABLE 24 SPECT/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER,  2021–2028 (USD MILLION) 89
6.4 PET/MR SYSTEMS 89
6.4.1 ADVANTAGES OFFERED OVER PET/CT SYSTEMS FOR DIAGNOSTIC PURPOSES TO PROPEL MARKET 89
TABLE 25 PET/MR MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION,  2021–2028 (USD MILLION) 90
TABLE 26 PET/MR MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 91
TABLE 27 PET/MR MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER,  2021–2028 (USD MILLION) 91
6.5 OCT/FMT SYSTEMS 92
6.5.1 INCREASING APPLICATIONS IN RETINAL DISEASE DIAGNOSIS TO DRIVE MARKET 92
TABLE 28 OCT/FMT MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION,  2021–2028 (USD MILLION) 92
TABLE 29 OCT/FMT MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 93
TABLE 30 OCT/FMT MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER,  2021–2028 (USD MILLION) 93
6.6 OTHER MULTIMODAL IMAGING SYSTEMS 94
TABLE 31 OTHER MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION,  2021–2028 (USD MILLION) 94
TABLE 32 OTHER MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 95
TABLE 33 OTHER MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER,  2021–2028 (USD MILLION) 95
7 MULTIMODAL IMAGING MARKET, BY APPLICATION 96
7.1 INTRODUCTION 97
TABLE 34 MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
7.2 ONCOLOGY 97
7.2.1 INCREASING DEMAND FOR EARLY AND ACCURATE CANCER DIAGNOSIS TO DRIVE MARKET 97
TABLE 35 MULTIMODAL IMAGING MARKET FOR ONCOLOGY APPLICATIONS, BY REGION,  2021–2028 (USD MILLION) 98
7.3 CARDIOLOGY 98
7.3.1 RISING PREVALENCE OF CARDIAC DISORDERS TO DRIVE GROWTH 98
TABLE 36 MULTIMODAL IMAGING MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION,  2021–2028 (USD MILLION) 99
7.4 OPHTHALMOLOGY 100
7.4.1 TECHNOLOGICAL INNOVATIONS IN OPHTHALMIC MULTIMODAL IMAGING SYSTEMS TO SUPPORT MARKET GROWTH 100
TABLE 37 MULTIMODAL IMAGING MARKET FOR OPHTHALMOLOGY APPLICATIONS, BY REGION,  2021–2028 (USD MILLION) 101
7.5 BRAIN & NEUROLOGY 101
7.5.1 INCREASING INCIDENCE OF BRAIN & NEUROLOGICAL DISORDERS TO PROPEL ADOPTION OF MULTIMODAL IMAGING SYSTEMS 101
TABLE 38 MULTIMODAL IMAGING MARKET FOR BRAIN & NEUROLOGY APPLICATIONS, BY REGION,  2021–2028 (USD MILLION) 102
7.6 RESEARCH 102
7.6.1 CAPABILITY TO PROVIDE COMPREHENSIVE AND SYNERGISTIC INSIGHTS INTO COMPLEX PHENOMENA TO SUPPORT MARKET GROWTH 102
TABLE 39 MULTIMODAL IMAGING MARKET FOR RESEARCH APPLICATIONS, BY REGION,  2021–2028 (USD MILLION) 103
7.7 OTHER APPLICATIONS 103
TABLE 40 MULTIMODAL IMAGING MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION) 104
8 MULTIMODAL IMAGING MARKET, BY END USER 105
8.1 INTRODUCTION 106
TABLE 41 MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 106
8.2 HOSPITALS 106
8.2.1 HIGH PROCEDURAL VOLUMES TO ENSURE SUSTAINED DEMAND FOR MULTIMODAL IMAGING 106
TABLE 42 MULTIMODAL IMAGING MARKET FOR HOSPITALS, BY REGION,  2021–2028 (USD MILLION) 107
8.3 DIAGNOSTIC IMAGING CENTERS 107
8.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH 107
TABLE 43 MULTIMODAL IMAGING MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021–2028 (USD MILLION) 108
8.4 ACADEMIC & RESEARCH INSTITUTES 108
8.4.1 GROWING AVAILABILITY OF RESEARCH GRANTS AND FUNDING TO DRIVE MARKET 108
TABLE 44 MULTIMODAL IMAGING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 109
8.5 OTHER END USERS 109
TABLE 45 MULTIMODAL IMAGING MARKET FOR OTHER END USERS, BY REGION,  2021–2028 (USD MILLION) 110
9 MULTIMODAL IMAGING MARKET, BY REGION 111
9.1 INTRODUCTION 112
TABLE 46 MULTIMODAL IMAGING MARKET, BY REGION, 2021–2028 (USD MILLION) 112
9.2 NORTH AMERICA 112
9.2.1 RECESSION IMPACT 112
FIGURE 25 NORTH AMERICA: MULTIMODAL IMAGING MARKET SNAPSHOT 113
TABLE 47 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY COUNTRY,  2021–2028 (USD MILLION) 114
TABLE 48 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 114
TABLE 49 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 115
TABLE 50 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY END USER,  2021–2028 (USD MILLION) 115
9.2.2 US 116
9.2.2.1 Rising geriatric population to drive market 116
TABLE 51 US: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
9.2.3 CANADA 117
9.2.3.1 Government investments to support market growth 117
TABLE 52 CANADA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
9.3 EUROPE 118
9.3.1 RECESSION IMPACT 118
TABLE 53 EUROPE: MULTIMODAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 54 EUROPE: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 119
TABLE 55 EUROPE: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 56 EUROPE: MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.3.2 GERMANY 121
9.3.2.1 Increasing prevalence of chronic diseases to drive market 121
TABLE 57 GERMANY: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 121
9.3.3 FRANCE 122
9.3.3.1 Rising number of diagnostic imaging centers to propel market 122
TABLE 58 FRANCE: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122
9.3.4 UK 123
9.3.4.1 Government initiatives to support market growth 123
TABLE 59 UK: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
9.3.5 ITALY 124
9.3.5.1 Availability of reimbursement coverage to support market growth 124
TABLE 60 ITALY: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
9.3.6 SPAIN 125
9.3.6.1 Increasing public funding for cell-based research to propel market 125
TABLE 61 SPAIN: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 125
9.3.7 REST OF EUROPE 126
TABLE 62 REST OF EUROPE: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 126
9.4 ASIA PACIFIC 127
9.4.1 RECESSION IMPACT 127
FIGURE 26 ASIA PACIFIC: MULTIMODAL IMAGING MARKET SNAPSHOT 128
TABLE 63 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY COUNTRY,  2021–2028 (USD MILLION) 129
TABLE 64 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 129
TABLE 65 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 130
TABLE 66 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY END USER,  2021–2028 (USD MILLION) 130
9.4.2 CHINA 131
9.4.2.1 Rapidly growing geriatric population to propel market 131
TABLE 67 CHINA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
9.4.3 JAPAN 132
9.4.3.1 High adoption of advanced technologies to support market growth 132
TABLE 68 JAPAN: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
9.4.4 INDIA 133
9.4.4.1 Rising prevalence of various chronic diseases to drive market 133
TABLE 69 INDIA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
9.4.5 AUSTRALIA 134
9.4.5.1 Increasing investments in research to provide opportunities for market growth 134
TABLE 70 AUSTRALIA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 134
9.4.6 SOUTH KOREA 135
9.4.6.1 Presence of well-developed healthcare system to propel market 135
TABLE 71 SOUTH KOREA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 135
9.4.7 REST OF ASIA PACIFIC 135
TABLE 72 REST OF ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 136
9.5 LATIN AMERICA 136
9.5.1 RECESSION IMPACT 136
TABLE 73 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY COUNTRY,  2021–2028 (USD MILLION) 137
TABLE 74 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 137
TABLE 75 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 138
TABLE 76 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY END USER,  2021–2028 (USD MILLION) 138
9.5.2 BRAZIL 139
9.5.2.1 Favorable demographic conditions to drive market 139
TABLE 77 BRAZIL: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139
9.5.3 MEXICO 140
9.5.3.1 Increased medical tourism and better government healthcare initiatives to drive market 140
TABLE 78 MEXICO: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
9.5.4 REST OF LATIN AMERICA 141
TABLE 79 REST OF LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 141
9.6 MIDDLE EAST & AFRICA 142
9.6.1 GROWING MEDICAL TOURISM TO DRIVE MARKET 142
9.6.2 RECESSION IMPACT 142
TABLE 80 MIDDLE EAST & AFRICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 143
TABLE 81 MIDDLE EAST & AFRICA: MULTIMODAL IMAGING MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 143
TABLE 82 MIDDLE EAST & AFRICA: MULTIMODAL IMAGING MARKET, BY END USER,  2021–2028 (USD MILLION) 144
10 COMPETITIVE LANDSCAPE 145
10.1 OVERVIEW 145
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 145
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIMODAL IMAGING MARKET 145
10.3 REVENUE SHARE ANALYSIS 146
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MULTIMODAL IMAGING MARKET, 2020–2022 146
10.4 MARKET SHARE ANALYSIS 147
FIGURE 28 MARKET SHARE ANALYSIS OF TOP PLAYERS IN MULTIMODAL IMAGING  MARKET, 2022 147
TABLE 83 MULTIMODAL IMAGING MARKET: DEGREE OF COMPETITION 147
10.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 149
10.5.1 STARS 149
10.5.2 EMERGING LEADERS 149
10.5.3 PERVASIVE PLAYERS 149
10.5.4 PARTICIPANTS 149
FIGURE 29 MULTIMODAL IMAGING MARKET: COMPANY EVALUATION MATRIX FOR  KEY PLAYERS, 2022 150
10.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 151
10.6.1 PROGRESSIVE COMPANIES 151
10.6.2 STARTING BLOCKS 151
10.6.3 RESPONSIVE COMPANIES 151
10.6.4 DYNAMIC COMPANIES 151
FIGURE 30 MULTIMODAL IMAGING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 152
10.7 COMPETITIVE BENCHMARKING 153
TABLE 84 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 153
TABLE 85 PRODUCT FOOTPRINT ANALYSIS OF COMPANIES 154
TABLE 86 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 155
10.8 COMPETITIVE SCENARIO AND TRENDS 156
TABLE 87 PRODUCT LAUNCHES, JANUARY 2020–JULY 2023 156
TABLE 88 DEALS, JANUARY 2020–JULY 2023 157
TABLE 89 OTHER DEVELOPMENTS, JANUARY 2020–JULY 2023 158
11 COMPANY PROFILES 160
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS 160
11.1.1 GE HEALTHCARE 160
TABLE 90 GE HEALTHCARE: COMPANY OVERVIEW 160
FIGURE 31 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 161
11.1.2 KONINKLIJKE PHILIPS N.V. 166
TABLE 91 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 166
FIGURE 32 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 167
11.1.3 CANON MEDICAL SYSTEMS CORPORATION 170
TABLE 92 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 170
FIGURE 33 CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022) 171
11.1.4 SIEMENS HEALTHINEERS 174
TABLE 93 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 174
FIGURE 34 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022) 175
11.1.5 ZEISS GROUP 178
TABLE 94 ZEISS GROUP: COMPANY OVERVIEW 178
FIGURE 35 CARL ZEISS MEDITEC GROUP: COMPANY SNAPSHOT (2022) 179
11.1.6 BRUKER 182
TABLE 95 BRUKER: COMPANY OVERVIEW 182
FIGURE 36 BRUKER: COMPANY SNAPSHOT (2022) 183
11.1.7 MEDISO LTD. 185
TABLE 96 MEDISO LTD.: COMPANY OVERVIEW 185
11.1.8 NEUSOFT CORPORATION. 187
TABLE 97 NEUSOFT CORPORATION: COMPANY OVERVIEW 187
11.1.9 INFRAREDX, INC. (PART OF NIPRO CORPORATION) 190
TABLE 98 INFRAREDX, INC.: COMPANY OVERVIEW 190
FIGURE 38 NIPRO CORPORATION: COMPANY SNAPSHOT (2022) 191
11.1.10 TOPCON CORPORATION 192
TABLE 99 TOPCON CORPORATION: COMPANY OVERVIEW 192
FIGURE 39 TOPCON CORPORATION: COMPANY SNAPSHOT (2022) 193
11.1.11 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD. 195
TABLE 100 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.: COMPANY OVERVIEW 195
11.1.12 HEIDELBERG ENGINEERING 198
TABLE 101 HEIDELBERG ENGINEERING: COMPANY OVERVIEW 198
11.1.13 SPECTRUM DYNAMICS MEDICAL 200
TABLE 102 SPECTRUM DYNAMICS MEDICAL: COMPANY OVERVIEW 200
11.1.14 MINFOUND MEDICAL SYSTEMS CO., LTD. 202
TABLE 103 MINFOUND MEDICAL SYSTEMS CO., LTD.: COMPANY OVERVIEW 202
11.1.15 KINDSWAY BIOTECH 204
TABLE 104 KINDSWAY BIOTECH: COMPANY OVERVIEW 204
11.2 OTHER COMPANIES 205
11.2.1 SOFIE BIOSCIENCES, INC. 205
11.2.2 REFLEXION MEDICAL, INC. 205
11.2.3 CUBRESA INC. 206
11.2.4 FUJIFILM CORPORATION 206
11.2.5 POSITRON 207
11.2.6 MR SOLUTIONS 208
11.2.7 ALCON INC. 209
11.2.8 ESSILOR INSTRUMENTS USA 209
11.2.9 NIDEK CO., LTD. 210
11.2.10 ZIEMER OPHTHALMIC SYSTEMS AG 210
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 211
12.1 DISCUSSION GUIDE 211
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 214
12.3 CUSTOMIZATION OPTIONS 216
12.4 RELATED REPORTS 216
12.5 AUTHOR DETAILS 217